America’s Employer Health-Care Bill Is Becoming a Business Problem

For millions of American workers, health insurance is presented as an employee benefit. For companies, however, it is increasingly behaving like a major operating expense—one that can influence compensation, hiring, retention and long-term financial planning.

The pressure is becoming harder to ignore. KFF’s 2025 Employer Health Benefits Survey found that the average annual premium for family employer-sponsored coverage reached $26,993, up 6% in a year. Workers contributed an average of $6,850, with employers absorbing the remainder. Employer-sponsored insurance covers roughly 154 million people under the age of 65.

The issue is not simply that insurance premiums are rising. Beneath the premium is a healthcare economy in which the price and use of medical services are both increasing, while new drugs and treatments are changing the composition of what employers pay for.

From Employee Benefit to Corporate Cost

The American employer-sponsored insurance system developed into a central source of coverage during the 20th century, linking healthcare to the workplace for a large share of the working-age population.

That arrangement creates a complicated economic relationship. Employers compete for workers partly through compensation and benefits, while insurers, hospitals, pharmaceutical companies, physicians and pharmacy-benefit managers operate within the same payment system.

When healthcare costs rise, employers have several choices. They can absorb the increase, raise employee contributions, redesign plans, negotiate with insurers and vendors, steer workers toward lower-cost providers or, in some cases, reduce the generosity of coverage.

Each option carries a trade-off.

Absorbing higher costs can put pressure on budgets and compensation. Shifting costs toward employees can make benefits less attractive and increase financial pressure on households. Narrower networks or more restrictive plans may lower spending but can also reduce convenience or choice.

That makes healthcare different from many ordinary business expenses. Companies cannot simply eliminate a product line or supplier. Health benefits are intertwined with their ability to attract and retain employees.

The Expensive Claims Problem

The arithmetic of employer healthcare is also changing because a relatively small number of expensive cases can have an outsized effect on a health plan.

Mercer reported in May 2026 that, in an analysis of 2.3 million members, people with annual claims above $100,000 represented about 1% of members but generated 34% of total employer healthcare spending in 2025.

Cancer is particularly important in this equation. Business Group on Health’s 2026 Employer Health Care Strategy Survey found that cancer was the top condition driving employer healthcare costs for the fourth consecutive year. The survey reported that 88% of participating employers identified cancer among their top three cost drivers in 2025.

The economics are not confined to hospital bills. Advances in cancer treatment can produce better outcomes while also introducing expensive medicines, complex diagnostics and specialized care. For employers, the challenge is therefore not simply reducing utilization. It is determining which spending produces enough health benefit to justify its cost.

Pharmacy Is Becoming a Strategic Issue

Prescription drugs add another layer of complexity.

Generic medicines can be relatively inexpensive and widely used, but the financial structure of pharmacy spending is increasingly influenced by specialty medicines, biologic treatments, gene and cell therapies and newer high-cost drugs.

Mercer estimates that prescription drug spending among large employers rose 9.4% in 2025. Its research indicates that pharmacy benefits remain one of the fastest-growing areas of employer health spending.

This changes the nature of cost management. A company may have thousands of employees using ordinary medicines without creating an exceptional financial burden, while a much smaller number of patients receiving complex therapies can account for a disproportionate share of expenditure.

That concentration is pushing employers to examine pharmacy-benefit-manager contracts, formularies, utilization controls and alternative purchasing arrangements more closely. Mercer reported in June 2026 that 41% of large employers were evaluating different contracting models with major pharmacy benefit managers, while 37% were evaluating new or emerging PBMs.

The objective is not necessarily to spend less on every medicine. Increasingly, it is to gain greater visibility into what the health plan is paying and whether the treatment represents good value.

The Workforce Trade-Off

The consequences eventually reach workers.

KFF found that employees contributed an average of 26% of family premiums in 2025. At smaller firms, the average share was considerably higher, at 36%, compared with 23% at larger firms.

Employers also face a less visible cost: the effect of healthcare decisions on recruitment and productivity.

Health benefits are part of total compensation. If medical costs consume more of an employer's compensation budget, companies may have less flexibility elsewhere. Alternatively, shifting more costs onto employees can reduce the perceived value of employment, particularly for lower-paid workers and families with significant medical needs.

This is why healthcare cost inflation can become a labor-market issue without becoming a conventional wage dispute.

What Employers Can Actually Change

The next phase is likely to involve more targeted cost management rather than a single solution.

Employers are already experimenting with high-performance provider networks, care navigation, cancer centers of excellence, preventive screening and alternative benefit designs. Business Group on Health reported that about half of surveyed employers planned to offer a cancer center of excellence in 2026, while another 23% were considering doing so by 2028.

Some companies are also reconsidering how much cost should be transferred to employees. Mercer reported that nearly half of large U.S. employers expected to make medical-plan changes for 2027 that could increase employee out-of-pocket costs, while others are pursuing plans that steer workers toward selected high-value providers.

The effectiveness of these strategies will depend on whether they reduce unnecessary spending without discouraging appropriate care.

That distinction matters. Cutting a benefit can reduce a company's immediate expense, but delaying effective treatment may simply move costs further into the future. Conversely, directing employees toward high-quality providers could reduce spending if it improves outcomes and avoids unnecessary procedures.

A Cost Problem With No Simple Buyer

The fundamental challenge is that no single participant controls the entire economics of American healthcare.

Employers pay premiums or claims. Workers use services and bear part of the cost. Insurers design networks and administer benefits. Hospitals negotiate reimbursement. Pharmaceutical companies determine prices and develop treatments. PBMs influence access and pharmacy economics. Governments establish rules and public programs.

Each participant responds to different incentives.

That makes the employer healthcare crisis less a story about one expensive product than about the cumulative economics of an interconnected system. WTW projected U.S. healthcare costs to rise 9.6% in 2026, while Business Group on Health found employers expecting a median 9% increase before plan changes.

The eventual question for corporate America may therefore be broader than how much it spends on healthcare. It may be whether the existing model can continue delivering increasingly sophisticated medical care without making health benefits an ever-larger constraint on the economics of employing people.

That question is likely to shape corporate benefit strategies, pharmaceutical negotiations and healthcare policy long after the next annual premium increase is announced.